ClinicalTrials.Veeva

Menu

Randomized Clinical Trial, Conventional Treatment-controlled, Studying the Efficacy of Plasma Rich in Growth Factor (PRGF®) in Alveolar Ridge Preservation After Simple Exodontia in the Anterior Region of Maxilla.

F

Fundación Eduardo Anitua

Status and phase

Completed
Phase 3

Conditions

Dental Implantation

Treatments

Device: Preparation of PRGF using Endoret technology
Drug: Alveolar ridge preservation with a PRP (PRGF-Endoret)
Procedure: Exodontia

Study type

Interventional

Funder types

Other

Identifiers

NCT04093583
2019-001167-75 (EudraCT Number)
FIBEA_04_EC_19_ALV

Details and patient eligibility

About

This RCT aims to study the efficacy and safety of PRGF-Endoret in alveolar ridge preservation in the aesthetic zone. The control group is the spontaneous healing occuring after the suturing of the alveolus. The primary endpoint is the bone regeneration measured in biopsies obtained from the regenerated alveolar bone.

Enrollment

46 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    • Subjects of both sexes with an age greater than or equal to 18 years.
  • Clinical indication for a simple exodontia in the aesthetic zone (from left 2nd premolar to the right 2nd premolar in the maxilla).
  • Need of a dental implant placement in the extraction site.
  • Availability to follow-up during the treatment period
  • Subjects with non-active periodontal disease.
  • Buccal dehiscence < than 25% in the vestibular table

Exclusion criteria

    • Presence of an active infection
  • Loss of any plate of the socket
  • Severe inflammation in the area of the exodontia previous to the intervention
  • Have previous diagnosis of a coagulopathy.
  • Have previous diagnosis of any autoinmune disease.
  • Have received radiotherapy, chemotherapy or immunosuppressive treatments, systemic corticosteroids and/or anticoagulants the 30 days prior to inclusion
  • Regular treatment with AINES or other antiinflammatory drugs
  • Previous history of chronic hepatitis or heatic cirrhosis
  • Positive markers for VHC, AgHBs, VIH I/II or Treponema pallidum
  • Uncontrolled diabetes mellitus (Glycosylated hemoglobin higher than 9%)
  • Subjects submitted to hemodyalisis
  • Presence of malignant tumour, haemangiomas or angioma in the exodontia region.
  • Previous history of ischemic cardiopathy in the last year.
  • Pregnancy or womens in childbearing age who do not take contraception measures.
  • Nursing womens
  • Metabolic bone disease
  • Ongoing treatment with biphosphonates both through oral or intravenous administration
  • Smoking habits (> 10 cigarrettes/day)
  • In general, any disability to participate in the study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

46 participants in 2 patient groups

Simple suture
Active Comparator group
Treatment:
Procedure: Exodontia
PRGF-Endoret
Experimental group
Treatment:
Procedure: Exodontia
Drug: Alveolar ridge preservation with a PRP (PRGF-Endoret)
Device: Preparation of PRGF using Endoret technology

Trial contacts and locations

5

Loading...

Central trial contact

Mikel Allende, PhD, MBA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems